Dr. Singh Discusses Immunotherapy Study in GIST – OncLive
OncLive |
Dr. Singh Discusses Immunotherapy Study in GIST
OncLive Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable … |
